Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients’ quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.
Understanding the link between EBV-infected B cells and multiple sclerosis
The Wistar Institute’s Paul M. Lieberman, Ph.D., and lab team led by senior staff scientist and first author, Samantha Soldan, Ph.D., have demonstrated how B
May 28, 2024